Charles Schwab’s Medpace MEDP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $112M | Buy |
211,847
+15,334
| +8% | +$7.08M | 0.01% | 723 |
|
|
2026
Q1 | $94.4M | Buy |
196,513
+6,726
| +4% | +$3.44M | 0.01% | 760 |
|
|
2025
Q4 | $107M | Buy |
189,787
+1,210
| +0.6% | +$687K | 0.02% | 702 |
|
|
2025
Q3 | $97M | Sell |
188,577
-5,914
| -3% | -$2.58M | 0.02% | 731 |
|
|
2025
Q2 | $61M | Sell |
194,491
-3,933
| -2% | -$1.18M | 0.01% | 973 |
|
|
2025
Q1 | $60.5M | Sell |
198,424
-2,622
| -1% | -$882K | 0.01% | 948 |
|
|
2024
Q4 | $66.8M | Buy |
201,046
+2,142
| +1% | +$726K | 0.01% | 909 |
|
|
2024
Q3 | $66.4M | Sell |
198,904
-7,576
| -4% | -$2.88M | 0.01% | 910 |
|
|
2024
Q2 | $85M | Buy |
206,480
+4,246
| +2% | +$1.68M | 0.02% | 722 |
|
|
2024
Q1 | $81.7M | Sell |
202,234
-9,981
| -5% | -$3.51M | 0.02% | 704 |
|
|
2023
Q4 | $65.1M | Sell |
212,215
-758
| -0.4% | -$205K | 0.02% | 797 |
|
|
2023
Q3 | $51.6M | Sell |
212,973
-11,817
| -5% | -$3.02M | 0.01% | 852 |
|
|
2023
Q2 | $54M | Sell |
224,790
-42,871
| -16% | -$8.91M | 0.02% | 822 |
|
|
2023
Q1 | $50.3M | Buy |
267,661
+569
| +0.2% | +$118K | 0.02% | 824 |
|
|
2022
Q4 | $56.7M | Sell |
267,092
-10,949
| -4% | -$2.19M | 0.02% | 722 |
|
|
2022
Q3 | $43.7M | Sell |
278,041
-3,060
| -1% | -$488K | 0.02% | 843 |
|
|
2022
Q2 | $42.1M | Sell |
281,101
-4,632
| -2% | -$671K | 0.01% | 861 |
|
|
2022
Q1 | $46.7M | Sell |
285,733
-1,100
| -0.4% | -$181K | 0.01% | 914 |
|
|
2021
Q4 | $62.4M | Buy |
286,833
+8,542
| +3% | +$1.79M | 0.02% | 752 |
|
|
2021
Q3 | $52.7M | Buy |
278,291
+16,953
| +6% | +$3.09M | 0.02% | 828 |
|
|
2021
Q2 | $46.2M | Buy |
261,338
+6,991
| +3% | +$1.21M | 0.02% | 932 |
|
|
2021
Q1 | $41.7M | Buy |
254,347
+15,905
| +7% | +$2.43M | 0.02% | 963 |
|
|
2020
Q4 | $33.2M | Sell |
238,442
-82,388
| -26% | -$10.4M | 0.01% | 1029 |
|
|
2020
Q3 | $35.9M | Sell |
320,830
-13,997
| -4% | -$1.62M | 0.02% | 848 |
|
|
2020
Q2 | $31.1M | Buy |
334,827
+80,819
| +32% | +$6.88M | 0.02% | 866 |
|
|
2020
Q1 | $18.6M | Buy |
254,008
+18,823
| +8% | +$1.63M | 0.01% | 1065 |
|
|
2019
Q4 | $19.8M | Buy |
235,185
+6,290
| +3% | +$487K | 0.01% | 1221 |
|
|
2019
Q3 | $19.2M | Sell |
228,895
-13,603
| -6% | -$1.03M | 0.01% | 1163 |
|
|
2019
Q2 | $15.9M | Buy |
242,498
+49,731
| +26% | +$2.87M | 0.01% | 1301 |
|
|
2019
Q1 | $11.4M | Buy |
192,767
+5,247
| +3% | +$313K | 0.01% | 1512 |
|
|
2018
Q4 | $9.93M | Sell |
187,520
-14,106
| -7% | -$774K | 0.01% | 1462 |
|
|
2018
Q3 | $12.1M | Buy |
201,626
+114,910
| +133% | +$6.29M | 0.01% | 1505 |
|
|
2018
Q2 | $3.73M | Buy |
86,716
+13,518
| +18% | +$546K | ﹤0.01% | 2144 |
|
|
2018
Q1 | $2.56M | Buy |
73,198
+15,132
| +26% | +$553K | ﹤0.01% | 2238 |
|
|
2017
Q4 | $2.11M | Buy |
58,066
+28,581
| +97% | +$1M | ﹤0.01% | 2282 |
|
|
2017
Q3 | $941K | Buy |
29,485
+1,411
| +5% | +$43.1K | ﹤0.01% | 2519 |
|
|
2017
Q2 | $815K | Buy |
28,074
+152
| +0.5% | +$4.26K | ﹤0.01% | 2530 |
|
|
2017
Q1 | $834K | Buy |
27,922
+1,368
| +5% | +$44.2K | ﹤0.01% | 2480 |
|
|
2016
Q4 | $958K | Buy |
26,554
+14,732
| +125% | +$491K | ﹤0.01% | 2443 |
|
|
2016
Q3 | $354K | Buy |
+11,822
| New | +$345K | ﹤0.01% | 2733 |
|
Other funds holding MEDP
WA
Charles Schwab's MEDP Position: Q2 2026 in Review
Charles Schwab increased its Medpace (MEDP) stake by 7.8% in Q2 2026, buying an estimated $7.08M and bringing the position to 211,847 shares worth $112M. The position accounts for 0.01% of the portfolio, ranked #723.
Charles Schwab first reported a position in MEDP in Q3 2016 and has held it in 40 quarters since. 694 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.
- Charles Schwab held 211,847 shares of Medpace worth $112M as of Q2 2026.
- Charles Schwab bought 15,334 Medpace shares in Q2 2026, an estimated $7.08M.
- Medpace made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #723 holding.
- Charles Schwab first reported a position in Medpace in Q3 2016 and has held it in 40 quarters since.
- 694 funds tracked by Wall St. Rank held Medpace as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.